DexCom (NASDAQ:DXCM) Rating Lowered to Hold at StockNews.com

StockNews.com cut shares of DexCom (NASDAQ:DXCM) from a buy rating to a hold rating in a research report released on Wednesday.

Other equities research analysts have also issued research reports about the company. BTIG Research decreased their price target on DexCom from $156.00 to $120.00 and set a buy rating on the stock in a research note on Friday, July 26th. Barclays dropped their price target on DexCom from $138.00 to $113.00 and set an equal weight rating for the company in a research report on Monday, July 29th. Morgan Stanley decreased their price objective on shares of DexCom from $120.00 to $75.00 and set an equal weight rating on the stock in a research report on Friday, July 26th. UBS Group dropped their target price on shares of DexCom from $163.00 to $95.00 and set a buy rating for the company in a report on Friday, July 26th. Finally, Stifel Nicolaus upped their price target on shares of DexCom from $90.00 to $100.00 and gave the company a buy rating in a report on Friday, August 23rd. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average price target of $112.25.

DexCom Price Performance

DexCom stock opened at $68.11 on Wednesday. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. DexCom has a one year low of $62.34 and a one year high of $142.00. The company has a market cap of $27.09 billion, a P/E ratio of 43.94, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. The business has a fifty day moving average of $70.19 and a two-hundred day moving average of $105.15.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm had revenue of $1 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same quarter last year, the business earned $0.34 earnings per share. The business’s revenue for the quarter was up 15.3% compared to the same quarter last year. As a group, analysts predict that DexCom will post 1.69 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the sale, the executive vice president now owns 66,249 shares in the company, valued at $4,607,617.95. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 652 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at approximately $4,607,617.95. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 1,824 shares of company stock worth $126,390. Insiders own 0.30% of the company’s stock.

Institutional Trading of DexCom

Institutional investors have recently made changes to their positions in the stock. Crewe Advisors LLC acquired a new position in DexCom in the first quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of DexCom in the 2nd quarter worth about $25,000. Riverview Trust Co acquired a new position in shares of DexCom in the 1st quarter valued at about $32,000. Sachetta LLC grew its holdings in shares of DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the period. Finally, Sound Income Strategies LLC increased its position in DexCom by 41.7% during the 1st quarter. Sound Income Strategies LLC now owns 340 shares of the medical device company’s stock worth $47,000 after purchasing an additional 100 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.